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Summary
Background: Treatment of genotype 1 hepatitis C virus (HCV) infection with
combination direct acting anti-virals is associated with very high rates of sus-
tained virological response (SVR). Daily combination of ledipasvir and sofosbuvir
for 12 weeks is approved for the treatment of genotype 1 HCV patients, though
noncirrhotic patients who are na€ıve to treatment with a baseline HCV RNA <6
million IU/mL can be treated for 8 weeks. This guidance stemmed from a post
hoc analysis of the ION 3 clinical trial, which demonstrated similar SVR for
patients treated with ledipasvir and sofosbuvir with or without ribavirin for 8 or
12 weeks.
Aim: To compare the SVR for 8 weeks vs 12 weeks of ledipasvir and sofosbu-
vir in HCV infected patients in a real-world setting.
Methods: We performed an observational real-world cohort study of treatment
success following 8 or 12 weeks of ledipasvir and sofosbuvir for treatment-na€ıve
genotype 1 HCV patients.
Results: A total of 826 patients were treated for either 8 (n=252) or 12 weeks
(n=574) with ledipasvir and sofosbuvir and achieved SVR rate of 95.3% and there
was no statistical difference in SVR rates in the two groups irrespective of any clini-
cal or virological variables.
Conclusions: In treatment-na€ıve HCV genotype 1 patients, SVR was 95% in those
treated for either 8 weeks or 12 weeks with ledipasvir and sofosbuvir. 8 week ledi-
pasvir and sofosbuvir can reduce costs without compromising outcomes for those
patients who qualify for such regimen.
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1 | INTRODUCTION
1.1 | Background
There is an estimated 80-185 million people infected with Hepatitis
C virus (HCV) worldwide.1,2 Despite the reduction in new infections
in recent years, morbidity and mortality related to chronic infection
are likely to increase.3 Since 2011, there has been the development
of several new regimens of direct acting anti-virals associated with
significant improvements in efficacy and tolerability in treatment of
HCV. Eradication of HCV is associated with decreased overall mor-
bidity and mortality as well as increased quality of life and reduced
healthcare utilisation.4,5 Based on the prevalence of infection and
availability of highly effective direct acting antivirals, treatment is
now recommended for all patients with chronic HCV infection.
However, due to the high wholesale cost of direct acting anti-
viral treatment regimens, one of the commonly cited barriers to
treatment is the cost of therapy.6 Despite this high cost, treatment
of na€ıve genotype 1 HCV patients is considered to be a cost-effec-
tive strategy when compared with other accepted medical prac-
tices.7-9 Ledipasvir and sofosbuvir fixed dose combination (LDV/
SOF) is approved by the Food and Drug Administration for the treat-
ment of genotype 1 HCV infection in treatment-na€ıve patients with
and without cirrhosis based on two registration trials called ION-1
and ION-3.10,11 The ION-3 study of treatment-na€ıve noncirrhotic
patients investigated LDV/SOF with or without ribavirin for 8 or
12 weeks and LDV/SOF for 12 weeks. Treatment-na€ıve noncirrhotic
patients infected with genotype 1 who received LDV/SOF for
8 weeks achieved an SVR rate of 94%. This SVR was not inferior to
a 12-week regimen of LDV/SOF in an intent-to-treat analysis.
Relapse rates were found to be higher in the cohort of patients ran-
domised to 8 weeks of treatment regardless of ribavirin. However,
in a post hoc analysis of the ribavirin-free treatment arms, patients
with baseline HCV RNA levels <6 million IU/mL were found to have
similarly high SVR rates and low relapse rates regardless of 8- or 12-
week treatment durations. While this analysis was not controlled,
the Food and Drug Administration included consideration of
8 weeks of LDV/SOF in genotype 1 treatment-na€ıve patients with-
out cirrhosis who have a pre-treatment viral load of <6 million IU/
mL.12 Despite the approval of the Food and Drug Administration,
the American Association for Study of Liver Disease/Infectious Dis-
eases Society of America guidelines for the treatment of HCV state
that shortening of therapy for less than 12 weeks is not recom-
mended in African-American patients, patients with Human Immun-
odeficiency Virus infection and patients with known interleukin-28B
polymorphism CT or TT.13 Guidelines from the European Association
for the Study of the Liver state that treatment may be shortened to
8 weeks in treatment-na€ıve patients without cirrhosis if their base-
line HCV RNA level is below 6 million (6.8 Log) IU/mL, however,
caution should be exercised especially in patients with F3 fibrosis,
pending confirmation of these results in real-life studies.14 Last, the
English National Health Service guidance recommends 8 weeks of
LDV/SOF for noncirrhotic treatment-na€ıve genotype 1 HCV infected
patients regardless of HCV viral load.15 Several heterogeneous real-
world cohort studies have reported excellent SVR rates for patients
treated for 8 weeks with LDV/SOFribavirin.16-23
The importance of these recommendations for the possible
shortening of duration cannot be underestimated as it is likely that
there is a significant population of patients who meet these criteria
who could benefit from a shortened, and thus less costly, course of
treatment. However, the baseline HCV viral load cut off of 6 million
IU/mL has been called into question, as the post hoc analysis was
underpowered and may reflect a statistical artefact.24
1.2 | Aim
We chose to evaluate SVR rates following LDV/SOF without rib-
avirin for genotype 1, treatment-na€ıve patients in a real-world cohort
of patients who have been treated for 8 or 12 weeks.
2 | PATIENT AND METHODS
2.1 | Study design/setting
The study cohort comprises treatment-naive, genotype 1 patients
treated in community and academic practices affiliated with the Trio
Health’s Innovation Platform. Patients received LDV/SOF for either
8 or 12 weeks at the discretion of their treating physician. Data
were collected through Trio Health’s Innovation Platform, a unique
platform that has the ability to collect and aggregate real-time data
for disease management. Baseline information as well as outcomes
data were collected through both the specialty pharmacies and clini-
cians in academic and community practices that work with Trio
Health and were entered into the portal via a combination of nightly
file feeds and manual user entry. In addition to data collection, the
portal also scrubbed and mapped data, applied proprietary logic to
identify errors, and prompted specialty pharmacies and clinicians to
input data to ensure all data were complete and accurate. For this
study, de-identified data were collected from this process, which
was approved as an Institutional Review Board exemption under
category 45 CFR 46.
This retrospective review of a prospectively defined cohort is
based on data from treatment-na€ıve patients who were treated for 8
or 12 weeks with LDV/SOF between October 2014 and March
2015. Patients were recruited in real-world community and academic
practices affiliated with Trio Healthcare. All patients were treatment
na€ıve and received LDV/SOF without ribavirin for 8 or 12 weeks.
The primary endpoint was SVR12, defined by a negative hepatitis C
viral load by polymerase chain reaction assessed at 12 weeks follow-
ing the completion of therapy. Treatment start and end dates were
defined by pharmacy dispensing records. Additional clinical charac-
teristics were recorded, including age, gender, ethnicity, physician-
reported fibrosis burden, transplant status, comorbidities (human
immunodeficiency virus [HIV], hepatitis B [HBV], diabetes), treatment
duration and physician practice type. Collected laboratory values
include HCV genotype, initial viral load, alanine and aspartate
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aminotransferase (ALT, AST), haemoglobin, and platelet count.
Assessment of HCV RNA was performed as per standard clinic prac-
tice by the treating physician and reported in standardised interna-
tional units. Fibrosis stage was determined by liver biopsy, serum
biomarkers and vibration controlled elastography assessment by
FibroScan as per the usual practice and was reported by the treating
physician. Fibrosis staging was not performed in 12.6% of the
patients enrolled,
2.2 | Statistical analysis
Associations between each individual potential predictor variable and
the SVR modelled both as a “per protocol” and “intention to treat”
were assessed. Predictor variables were entered into univariable
ordinal regression models with fibrosis stage as the ordinal outcome.
Predictor variables with two-tailed P≤.25 were entered into multi-
variable logistic regression models. Manual backward stepwise elimi-
nation was used to generate the best-fitting multivariable logistic
model. Forced adjustments for severe fibrosis and thrombocytopenia
were subsequently performed for each variable in logistic regression
analyses. These analyses were repeated for the overall cohort in
addition to subgroup analyses for patients treated for 8 and
12 weeks.
3 | RESULTS
3.1 | Treatment cohort
A total of 826 patients received LDV/SOF treatment for either 8 or
12 weeks. Two hundred and fifty two patients were treated for
8 weeks and 574 were treated for 12 weeks (Figure 1). Fifty-one
per cent of patients were male, 52% were Caucasian and 17% of
patients were African American. All patients were treatment-na€ıve.
The majority (63%) of patients were treated in community practices
and there was no difference in the duration of therapy between
community and academic practices. Baseline characteristics of the
cohort are presented in Table 1. Patients receiving 12 weeks of
treatment were significantly older, more likely to be male gender,
have more advanced fibrosis, have lower platelet counts, and have
higher viral loads.
There were 587 who were deemed not to have liver cirrhosis by
liver biopsy, FibroScan or serum fibrosis markers, and had a platelet
count of >100 000/lL and an AST to platelet index (APRI) of <1.0.
Two hundred and thirty-nine patients did not have formal staging of
liver fibrosis or had a platelet count of <100 000/lL or an APRI of
>1.0. Sustained virological response rates were assessed for the
entire cohort of patients (n=826) and for those formally deemed not
to have liver cirrhosis.
3.2 | Virological outcomes
SVR12 was achieved in 787/826 (95.3%) of patients in the entire
cohort. Twenty-one patients were lost to follow-up, seven patients
discontinued therapy and there were two deaths during treatment.
None of the treatment discontinuations were related to study medi-
cations. Patients lost to follow-up or those that discontinued treat-
ment are considered treatment failures in the intent-to-treat
analysis. Intent-to-treat SVR12 was 95.2% for patients treated for
8 weeks and 95.3% for patients treated for 12 weeks. There was no
difference in SVR by viral subtype regardless of duration of treat-
ment (Figure 2). There were nine relapses in total, with three
patients treated for 8 weeks for a relapse rate of 1.2%. Six patients
in the 12-weeks treatment group relapsed for a relapse rate of 1.1%
(Figure 1 and Table 2). Five hundred and seventy-seven patients met
the HCV viral load of <6 million IU/mL to receive 8 weeks of LDV/
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F IGURE 1 Distribution of all patients who were treated with
LDV/SOF for 8 and 12 weeks. The number of patient achieving SVR
and those experiencing relapse are shown for 8 and 12 weeks of
treatment. The numbers of patient who died, discontinued therapy
or who were lost to follow-up (LTFU) are displayed for both
treatment durations
TABLE 1 Baseline characteristics of patients
8 weeks
(n=252)
12 weeks
(n=574) P value
Age >65 years, n (%) 65 (25.8) 188 (32.8) .05
Male, n (%) 114 (45.2) 310 (54.0) .02
Race, n (%)
Black 37 (15.9) 106 (19.8) .07
Hispanic/Latin 14 (6.0) 31 (5.8)
White 145 (62.2) 282 (52.7)
Genotype 1a, n (%) 172 (69.4) 380 (66.9) .86
Initial viral load, IU/mL
median (106) (IQR)
1.33 (0.39-2.33) 2.56 (0/89-6.23) .0001
Academic practice, n (%) 83 (32.9) 219 (38.2) .16
Advanced fibrosis, n (%) 32 (12.7) 142 (24.7) .0001
Platelets <100 K/mL,
n (%)
2 (0.79) 21 (3.7) .02
Post-transplant, N (%) 1 (0.4) 4 (0.7) .60
Diabetes 24 (9.8) 75 (13.3) .04
542 | CURRY ET AL.
SOF. Two hundred and fifty-one patients (38%) who were received
8 weeks of treatment achieved and SVR of 95.2%, while 416 (62%)
patients with HCV RNA levels <6 million IU/mL and were eligible for
8 weeks but were treated for 12 weeks, had a similar SVR of 94.9%.
Excluding patients without a formal stage of liver fibrosis, a pla-
telet count of <100 000/mL and an APRI of >1.0, the SVR rate was
97% and was not different in those treated for 8 weeks (97%) and
those treated for 12 weeks (97%). In this cohort, SVR was similar
across all stage of liver fibrosis (F0-3) for 8 and 12 weeks (Figure 3).
There was no difference in SVR noted in those who had diabetes
mellitus vs those that did not with SVR rates of 95% seen in both
cohorts. Per protocol analysis demonstrated that SVR rate in diabet-
ics treated for 8 weeks was 96% and 98% in those treated for
12 weeks. There were 143 (17%) African Americans included in the
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F IGURE 2 Overall SVR rates for all patients treated with LDV/SOF for 8 weeks (95%) and 12 weeks (95%) (A); SVR rates for patients with
known genotype 1a vs 1b for patients treated for 8 weeks (blue) and 12 weeks (purple) (B); SVR rates patients with known fibrosis scores
receiving 8 weeks (blue) vs 12 weeks (purple) (C)
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study. SVR was achieved in 96% of African American patients trea-
ted with LDV/SOF. There were nine relapses in the entire cohort
and six relapses occurred in African American patients. While the
SVR rate in the patients treated for 8 weeks (n=37) was numerically
lower than those treated for 12 weeks (n=106), this did not reach
statistical significance. (89% vs 94%; P=.29). Again while there was
no statistically significant difference in SVR rate noted between Afri-
can American patients treated for 8 weeks and those African Ameri-
can patients who eligible to received for 8 weeks but were treated
for 12 weeks (89% vs 95%; P=.28), the result was numerically lower.
We examined the effect of baseline predictors on virological out-
come and we were unable to identify any variable that was signifi-
cantly associated with treatment failure in either per-protocol or
intention-to-treat analyses in multivariable logistic regression models.
4 | DISCUSSION
The efficacy and better tolerability of all oral anti-viral regimens in
patients with chronic HCV infection is well established with SVR
rates 21-fold higher now than in the interferon era.25 These
improvements in SVR are noted across multiple patient popula-
tions leading to the widespread use of these agents even in
patients with advanced disease.26–28 However, due to the high
cost of these regimens and the implementation of a triage system
by health care agencies to allocate treatment, there are still signifi-
cant populations of patients who have not yet been treated and
are at risk of disease progression. Socioeconomic reasons have
now replaced medical contraindications as the primary reason for
patients to be denied access to treatment.29,30 Shortening the
duration of treatment could significantly reduce the costs of treat-
ment and in many cases, can be cost-saving. Post hoc analysis of
the ION-3 registration trial identified a cohort of treatment-na€ıve
noncirrhotic patients with low viral load who are likely to have
similar SVR rates to patients who received a 12-week treatment
course of LDV/SOF. In view of this the Food and Drug Adminis-
tration included the option for an 8-week duration of treatment
for patients meeting these pretreatment criteria. International
guidelines have suggested caution in the use of treatment
regimens of less than 12 weeks in this population pending the
results of real-world studies addressing shorter durations of treat-
ment. Reducing the duration of treatment for these patients could
result in significant cost savings and possibly allow more patients
to receive much needed anti-viral therapy.
In this real-world experience of HCV treatment in genotype1
treatment-na€ıve patients, high SVR rates, comparable to that was
observed in registration trials, were achieved. There were no differ-
ences in SVR between the 8- and 12-week cohorts and no differ-
ences were observed in SVR across genotype subtype or fibrosis
stage. This analysis of a real-world cohort of patients treated in com-
munity and academic medical centres included some patients who
did not have a formal assessment of liver fibrosis and had platelet
counts of <100 000/lL or an APRI of >1.0. When we excluded
these patients from the SVR analysis, the SVR rates were 97%.
Five hundred and seventy-seven patients met the HCV viral load
of <6 million IU/mL criteria to receive 8 weeks of LDV/SOF. Two
hundred and fifty-one patients (38%) received 8 weeks of treatment
and SVR was achieved in 95.2% while 416 (62%) patients with HCV
RNA levels <6 million IU/mL were treated for 12 weeks and SVR
was achieved in 94.9%. Shortening the course of treatment by
4 weeks for these 416 patients could possibly have resulted in
significant cost savings across the entire cohort.
Our data are similar to that recently published by Ioannou and
colleagues who analysed the real-world effectiveness of DAA treat-
ment in the Veterans Affairs National Health Care System. Twenty-
seven per cent of patients receiving LDV/SOF were treated for
8 weeks and achieved SVR rates of 94.3%.31 In a subgroup analysis
of those treatment-na€ıve noncirrhotic patients with HCV RNA levels
<6 million IU/mL, 48% were treated for 8 weeks and achieved SVR
of 95%, similar to the SVR achieved by the 38% of patients in our
study treated for 8 weeks.
Prior studies have shown higher rates of virological relapse in
genotype 1a patients after 8 weeks of treatment. In this real-world
cohort, very low and no difference was observed in relapse rates
across genotype subtype and treatment duration.
Our study is limited by the retrospective nonrandomised design
that precludes rigid comparisons of the treatment duration. In addi-
tion, treatment duration was at the discretion of the treating
TABLE 2 Characteristics of all relapses
Practice type Patient age Patient gender Patient ethnicity (group) Genotype group Actual regimen name Duration Baseline VL
Academic 64 F Black 1A LDV-SOF 8 805 000
Academic 67 M White 1A LDV-SOF 8 646 400
Community 78 F Black 1A LDV-SOF 8 1 973 539
Community 61 F White 1A LDV-SOF 12 3 020 000
Community 61 M Black 1A LDV-SOF 12 3 569 042
Community 60 F White 1A LDV-SOF 12 11 291 000
Community 58 M Black 1UNKNOWN LDV-SOF 12 2 245 736
Academic 46 M Unknown 1A LDV-SOF 12 2 456 117
Community 63 F Black 1B LDV-SOF 12 2 977 629
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F IGURE 3 Overall SVR rates for patients without cirrhosis treated with LDV/SOF for 8 and 12 weeks (A); SVR rates for patients without
cirrhosis with known genotype 1a vereses 1b receiving 8 weeks (blue) and 12 weeks (purple) (B); and SVR rates for patient with known
fibrosis scores receiving 8 weeks (blue) and 12 weeks (purple) (C)
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physician and as such there were significantly more patients older
than 65 years, of male gender, diabetics and more advanced fibrosis
patients in the cohort treated for 12 weeks. Details such as IL28B
polymorphism were not available, however this assay is rarely used
in the current era of direct acting anti-viral therapy. Additionally we
do not have data on concomitant use of medications such as acid-
reducing medications for this study, though this is unlikely to have
changed the results.32 Our entire cohort included some patients who
did not have a formal assessment of liver fibrosis as well as patients
who had platelet count of <100 000/lL. To more stringently evalu-
ate the efficacy of LDV/SOF for 8 vs 12 weeks in true non-cirrhotic
patients, we further analysed the SVR rates in a cohort with formal
assessment of liver fibrosis, platelet count of >100 000/lL and an
APRI of >1.0 and showed excellent SVR rates of 97% in the 8 and
12 weeks cohorts (Figure 3).
Further limitations include the small numbers of patients for sub-
group anlaysis, thus limiting the power of this study to determine
significant differences in SVR by treatment duration in these sub-
groups. The overall SVR rate for African Americans treated with
LDV/SOF was 96%. The numbers of African American patients trea-
ted for 8 weeks in this study is small and though the SVR rates are
not significantly different for 8 weeks and 12 weeks of treatment,
there is a numerically lower SVR rate and relapse is more commonly
seen in African American patients in this study (Table 2). The small
numbers of African American patients in this study limits any defini-
tive conclusions regarding 8 vs 12 weeks in this population. As with
other studies of African American patients, which demonstrate simi-
lar SVR rates for 8 and 12 weeks we suggest that caution be used
in shortening treatment in this population because of a higher
relapse rate.33,34
Despite these limitations, our study has comparable rates of SVR
to that observed in registration trials for LDV/SOV.10 Our study also
supports the real-world effectiveness study by Ioannou and col-
leagues for the VA cooperative and supports the VA treatment
guidelines and the English National Health Service guidance on
shortening duration of treatment in noncirrhotic treatment-na€ıve
patients with HCV RNA <6 million IU/mL.31,35 The generalisability of
the clinical data from ION-3 has also been demonstrated by multiple
other, real-world studies comparing 8 vs 12 weeks of LDV/SOF mul-
tiple geographies and patient care settings including patients with
HIV disease.17,19,20,22,36–38
In conclusion, our study supports the FDA recommendation that
clinicians should consider 8 weeks of LDV/SOF for initial treatment
of HCV genotype 1, treatment-na€ıve, non-cirrhotic patients.
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